Patient and dosimetric predictors of genitourinary and bowel quality of life after prostate SBRT: Secondary analysis of a multi-institutional trial

We investigated associations between dosimetric parameters and quality of life (QOL) in patients treated with prostate SBRT on a prospective phase II trial. Rectal doses (e.g. Dmax) were significantly associated with decreased bowel QOL at both 1 month and 2 years. Patients with rectum Dmax greater than the median 37.4 Gy were more likely to have bowel symptoms at 2 years. Patient factors, but not bladder or urethral doses, were associated with urinary QOL.

https://ift.tt/2NPLs3w